ARTICLE | Product Development
Vir, Alnylam look to year-end to start trials of siRNA product for COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
May 5, 2020 1:45 AM UTC
Updated on May 5, 2020 at 7:54 PM UTC
Vir and Alnylam are planning to begin clinical trials for their antiviral siRNA candidate around year-end. But because the compound will be Alnylam’s first inhaled oligo to enter the clinic, it may face different regulatory challenges than COVID-19 therapies with more established routes of administration.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and partner Vir Biotechnology Inc. (NASDAQ:VIR) plan to meet with FDA and other regulatory authorities soon to discuss an accelerated path for an IND or equivalent submission for an inhaled formulation of VIR-2703 (ALN-COV) to treat or prevent COVID-19. ...